Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration.

Post TE, Kamerling IMC, van Rossen RCJM, Burggraaf J, Stevens J, Dijkmans AC, Heijerman HGM, Touw DJ, van Velzen AJ, Wilms EB.

Eur J Hosp Pharm. 2018 Nov;25(6):337-339. doi: 10.1136/ejhpharm-2016-001128. Epub 2017 Mar 18.

PMID:
31157054
2.

Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.

van Velzen AJ, Uges JWF, Heijerman HGM, Arets BGM, Nuijsink M, van der Wiel-Kooij EC, van Maarseveen EM, van Zanten GA, Pullens B, Touw DJ, Janssens HM.

Br J Clin Pharmacol. 2019 Sep;85(9):1984-1993. doi: 10.1111/bcp.13988. Epub 2019 Jul 10.

3.

Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms.

Georgescu MT, Moorehead PC, van Velzen AS, Nesbitt K, Reipert BM, Steinitz KN, Schuster M, Hough C, Lillicrap D.

Haematologica. 2018 Aug;103(8):1403-1413. doi: 10.3324/haematol.2018.189852. Epub 2018 Apr 19.

4.

Desmopressin in moderate hemophilia A patients: a treatment worth considering.

Loomans JI, Kruip MJHA, Carcao M, Jackson S, van Velzen AS, Peters M, Santagostino E, Platokouki H, Beckers E, Voorberg J, van der Bom JG, Fijnvandraat K; RISE consortium.

Haematologica. 2018 Mar;103(3):550-557. doi: 10.3324/haematol.2017.180059. Epub 2018 Jan 5.

5.

Early cellular interactions and immune transcriptome profiles in human factor VIII-exposed hemophilia A mice.

Lai JD, Cartier D, Hartholt RB, Swystun LL, van Velzen AS, den Haan JMM, Hough C, Voorberg J, Lillicrap D.

J Thromb Haemost. 2018 Mar;16(3):533-545. doi: 10.1111/jth.13936. Epub 2018 Feb 2.

PMID:
29285874
6.

To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.

Hartholt RB, van Velzen AS, Peyron I, Ten Brinke A, Fijnvandraat K, Voorberg J.

Blood Rev. 2017 Sep;31(5):339-347. doi: 10.1016/j.blre.2017.07.001. Epub 2017 Jul 4. Review.

PMID:
28716211
7.

Minerals and Sarcopenia; The Role of Calcium, Iron, Magnesium, Phosphorus, Potassium, Selenium, Sodium, and Zinc on Muscle Mass, Muscle Strength, and Physical Performance in Older Adults: A Systematic Review.

van Dronkelaar C, van Velzen A, Abdelrazek M, van der Steen A, Weijs PJM, Tieland M.

J Am Med Dir Assoc. 2018 Jan;19(1):6-11.e3. doi: 10.1016/j.jamda.2017.05.026. Epub 2017 Jul 12. Review.

PMID:
28711425
8.

Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.

van Velzen AS, Eckhardt CL, Peters M, Leebeek FWG, Escuriola-Ettingshausen C, Hermans C, Keenan R, Astermark J, Male C, Peerlinck K, le Cessie S, van der Bom JG, Fijnvandraat K.

J Thromb Haemost. 2017 Jul;15(7):1422-1429. doi: 10.1111/jth.13711. Epub 2017 Jun 2.

9.

Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations.

Loomans JI, van Velzen AS, Eckhardt CL, Peters M, Mäkipernaa A, Holmstrom M, Brons PP, Dors N, Haya S, Voorberg J, van der Bom JG, Fijnvandraat K.

J Thromb Haemost. 2017 Feb;15(2):246-254. doi: 10.1111/jth.13581. Epub 2017 Feb 3.

10.

Summary report of the First International Conference on inhibitors in haemophilia A.

Lacroix-Desmazes S, Scott DW, Goudemand J, Van Den Berg M, Makris M, Van Velzen AS, Santagostino E, Lillicrap D, Rosendaal FR, Hilger A, Sauna ZE, Oldenburg J, Mantovani L, Mancuso ME, Kessler C, Hay CRM, Knoebl P, Di Minno G, Hoots K, Bok A, Brooker M, Buoso E, Mannucci PM, Peyvandi F.

Blood Transfus. 2017 Oct;15(6):568-576. doi: 10.2450/2016.0252-16. Epub 2016 Nov 25. No abstract available.

11.

Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A.

Castaman G, Eckhardt C, van Velzen A, Linari S, Fijnvandraat K.

Semin Thromb Hemost. 2016 Jul;42(5):507-12. doi: 10.1055/s-0036-1571309. Epub 2016 May 5. Review.

PMID:
27148839
12.

Dissecting intensive treatment as risk factor for inhibitor development in haemophilia.

Eckhardt CL, van Velzen AS, Fijnvandraat CJ, van der Bom JG.

Haemophilia. 2016 May;22(3):e241-4. doi: 10.1111/hae.12944. Epub 2016 Apr 14. No abstract available.

PMID:
27076357
13.

Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.

van Velzen AJ, Bos AC, Touw DJ, Tiddens HA, Heijerman HG, Janssens HM.

J Aerosol Med Pulm Drug Deliv. 2016 Jun;29(3):273-80. doi: 10.1089/jamp.2015.1259. Epub 2015 Dec 30.

PMID:
26716357
14.

The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors.

van Velzen AS, Eckhardt CL, Streefkerk N, Peters M, Hart DP, Hamulyak K, Klamroth R, Meijer K, Nijziel M, Schinco P, Yee TT, van der Bom JG, Fijnvandraat K; INSIGHT study group.

Thromb Haemost. 2016 Mar;115(3):543-50. doi: 10.1160/TH15-03-0212. Epub 2015 Nov 19.

PMID:
26582077
15.

Inhibitor development and mortality in non-severe hemophilia A.

Eckhardt CL, Loomans JI, van Velzen AS, Peters M, Mauser-Bunschoten EP, Schwaab R, Mazzucconi MG, Tagliaferri A, Siegmund B, Reitter-Pfoertner SE, van der Bom JG, Fijnvandraat K; INSIGHT Study Group.

J Thromb Haemost. 2015 Jul;13(7):1217-25. doi: 10.1111/jth.12990. Epub 2015 Jun 10.

16.

Inhibitors in nonsevere haemophilia A: outcome and eradication strategies.

van Velzen AS, Eckhardt CL, Hart DP, Peters M, Rangarajan S, Mancuso ME, Smiers FJ, Khair K, Petrini P, Jiménez-Yuste V, Hay CR, van der Bom JG, Yee TT, Fijnvandraat K; INSIGHT study group.

Thromb Haemost. 2015 Jul;114(1):46-55. doi: 10.1160/TH14-11-0940. Epub 2015 Apr 16.

PMID:
25879247
17.

The influence of breathing mode on tobramycin serum levels using the I-neb AAD system in adults with cystic fibrosis.

van Velzen AJ, Uges JW, Le Brun PP, Shahbabai P, Touw DJ, Heijerman HG.

J Cyst Fibros. 2015 Nov;14(6):748-54. doi: 10.1016/j.jcf.2015.01.002. Epub 2015 Jan 27.

18.

Systemic absorption of nasally administered tobramycin and colistin in patients with cystic fibrosis.

Berkhout MC, van Velzen AJ, Touw DJ, de Kok BM, Fokkens WJ, Heijerman HG.

J Antimicrob Chemother. 2014 Nov;69(11):3112-5. doi: 10.1093/jac/dku239. Epub 2014 Jul 11.

PMID:
25016384
19.

Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review.

van Velzen AS, Peters M, van der Bom JG, Fijnvandraat K.

Br J Haematol. 2014 Aug;166(4):485-95. doi: 10.1111/bjh.12942. Epub 2014 May 16. Review.

PMID:
24837603
20.

Ingestion of smoke fluid: Be aware of diethylene glycol.

van Velzen A, Vermeeren Y, van Riel A, Meulenbelt J, de Vries I.

Clin Toxicol (Phila). 2013 Nov;51(9):907. doi: 10.3109/15563650.2013.833621. Epub 2013 Aug 30. No abstract available.

PMID:
23992443
21.

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.

Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, Cnossen MH, Dors N, Escuriola-Ettingshausen C, Hamulyak K, Hart DP, Hay CR, Haya S, van Heerde WL, Hermans C, Holmström M, Jimenez-Yuste V, Keenan RD, Klamroth R, Laros-van Gorkom BA, Leebeek FW, Liesner R, Mäkipernaa A, Male C, Mauser-Bunschoten E, Mazzucconi MG, McRae S, Meijer K, Mitchell M, Morfini M, Nijziel M, Oldenburg J, Peerlinck K, Petrini P, Platokouki H, Reitter-Pfoertner SE, Santagostino E, Schinco P, Smiers FJ, Siegmund B, Tagliaferri A, Yee TT, Kamphuisen PW, van der Bom JG, Fijnvandraat K; INSIGHT Study Group.

Blood. 2013 Sep 12;122(11):1954-62. doi: 10.1182/blood-2013-02-483263. Epub 2013 Aug 7. Erratum in: Blood. 2014 May 8;123(19):3056.

PMID:
23926300
22.

Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone.

Villarroel C, Merino PM, López P, Eyzaguirre FC, Van Velzen A, Iñiguez G, Codner E.

Hum Reprod. 2011 Oct;26(10):2861-8. doi: 10.1093/humrep/der223. Epub 2011 Jul 21.

PMID:
21784736
23.

Role of maternal 5-HT(1A) receptor in programming offspring emotional and physical development.

van Velzen A, Toth M.

Genes Brain Behav. 2010 Nov;9(8):877-85. doi: 10.1111/j.1601-183X.2010.00625.x.

24.

Bioavailability of sodium nitrite from an aqueous solution in healthy adults.

Hunault CC, van Velzen AG, Sips AJ, Schothorst RC, Meulenbelt J.

Toxicol Lett. 2009 Oct 8;190(1):48-53. doi: 10.1016/j.toxlet.2009.06.865. Epub 2009 Jul 1.

PMID:
19576277
25.

Feasibility of weaning and direct extubation from open lung high-frequency ventilation in preterm infants.

van Velzen A, De Jaegere A, van der Lee J, van Kaam A.

Pediatr Crit Care Med. 2009 Jan;10(1):71-5. doi: 10.1097/PCC.0b013e3181936fbe.

PMID:
19057441
26.

The oral bioavailability of nitrate from nitrate-rich vegetables in humans.

van Velzen AG, Sips AJ, Schothorst RC, Lambers AC, Meulenbelt J.

Toxicol Lett. 2008 Oct 1;181(3):177-81. doi: 10.1016/j.toxlet.2008.07.019. Epub 2008 Aug 3.

PMID:
18723086
27.

A case series of xylometazoline overdose in children.

van Velzen AG, van Riel AJ, Hunault C, van Riemsdijk TE, de Vries I, Meulenbelt J.

Clin Toxicol (Phila). 2007;45(3):290-4.

PMID:
17453884
28.

Early treatment of trans-tibial amputees: retrospective analysis of early fitting and elastic bandaging.

van Velzen AD, Nederhand MJ, Emmelot CH, Ijzerman MJ.

Prosthet Orthot Int. 2005 Apr;29(1):3-12.

PMID:
16180373
29.

Hepatic and extrahepatic scavenger receptors: function in relation to disease.

Terpstra V, van Amersfoort ES, van Velzen AG, Kuiper J, van Berkel TJ.

Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):1860-72. Review. No abstract available.

PMID:
10938005
30.

Engineering aspects of beta-lactam biosynthesis.

van den Berg MA, Bovenberg RA, de Laat WT, van Velzen AG.

Antonie Van Leeuwenhoek. 1999 Jan-Feb;75(1-2):155-61. Review.

PMID:
10422588
31.

The role of scavenger receptor class A in the adhesion of cells is dependent on cell type and cellular activation state.

van Velzen AG, Suzuki H, Kodama T, van Berkel TJ.

Exp Cell Res. 1999 Jul 10;250(1):264-71.

PMID:
10388540
32.

Uptake and catabolism of modified LDL in scavenger-receptor class A type I/II knock-out mice.

Van Berkel TJ, Van Velzen A, Kruijt JK, Suzuki H, Kodama T.

Biochem J. 1998 Apr 1;331 ( Pt 1):29-35.

33.

Human monocyte-derived macrophages express an approximately 120-kD Ox-LDL binding protein with strong identity to CD68.

van der Kooij MA, von der Mark EM, Kruijt JK, van Velzen A, van Berkel TJ, Morand OH.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3107-16.

PMID:
9409300
34.

Characterization of a receptor for oxidized low-density lipoproteins on rat Kupffer cells: similarity to macrosialin.

Van Velzen AG, Da Silva RP, Gordon S, Van Berkel TJ.

Biochem J. 1997 Mar 1;322 ( Pt 2):411-5.

35.

LDL receptor-independent and -dependent uptake of lipoproteins.

van Berkel TJ, Fluiter K, van Velzen AG, Vogelezang CJ, Ziere GJ.

Atherosclerosis. 1995 Dec;118 Suppl:S43-50. Review.

PMID:
8821464
36.

Epidermal growth factor induces rapid and transient association of phospholipase C-gamma 1 with EGF-receptor and filamentous actin at membrane ruffles of A431 cells.

Diakonova M, Payrastre B, van Velzen AG, Hage WJ, van Bergen en Henegouwen PM, Boonstra J, Cremers FF, Humbel BM.

J Cell Sci. 1995 Jun;108 ( Pt 6):2499-509.

37.

[Patellar chondropathy in family practice].

van Velzen AP.

Ned Tijdschr Geneeskd. 1991 Apr 27;135(17):775. Dutch. No abstract available.

PMID:
2046774
38.

[Aspartame, a sweet alternative].

van Velzen A.

Ned Tijdschr Geneeskd. 1988 Jul 30;132(31):1452. Dutch. No abstract available.

PMID:
3412526
39.

A biomechanical model for flexion torques of human arm muscles as a function of elbow angle.

van Zuylen EJ, van Velzen A, Denier van der Gon JJ.

J Biomech. 1988;21(3):183-90.

PMID:
3379078

Supplemental Content

Loading ...
Support Center